2025
Cardiac Biomarkers, Subclinical Brain Vascular Changes, and Cognitive Decline: Post Hoc Analysis of the SPRINT Trial
Zhang W, Ascher S, Dolui S, Nasrallah I, Lu Y, Neitzel J, Toledo E, Glodzik L, Shaltout H, Hughes T, Berry J, Ma Y. Cardiac Biomarkers, Subclinical Brain Vascular Changes, and Cognitive Decline: Post Hoc Analysis of the SPRINT Trial. The Journals Of Gerontology Series A 2025, 80: glaf005. PMID: 39774657, PMCID: PMC12070484, DOI: 10.1093/gerona/glaf005.Peer-Reviewed Original ResearchConceptsGlobal cognitive functionCognitive declineBrain tissue volumesCognitive functionSubclinical cardiovascular diseasePost Hoc AnalysisIntensive BP treatmentDomain-specific measuresCerebral blood flowWhite matter lesionsAssociated with accelerated cognitive declineCardiovascular diseaseAccelerated cognitive declineBrain vascular changesHoc AnalysisCardiac biomarkersLevels of high-sensitivity cardiac troponin TN-terminal pro-B-type natriuretic peptideBP treatmentBlood pressureElevated levelsHigh-sensitivity cardiac troponin TPro-B-type natriuretic peptideBlood flowNT-proBNP levels
2023
Correlates of Spontaneous Blood Pressure Reduction Following Severe Inpatient Hypertension Development
Garg K, Staunton M, Peixoto A, Wilson F, Ghazi L. Correlates of Spontaneous Blood Pressure Reduction Following Severe Inpatient Hypertension Development. American Journal Of Hypertension 2023, 37: 273-279. PMID: 37988620, DOI: 10.1093/ajh/hpad112.Peer-Reviewed Original ResearchBlood pressure reductionSevere hypertensionBP reductionPressure reductionRetrospective cohort studyChronic pulmonary diseaseMultivariable logistic regressionFuture treatment decisionsAntihypertensive medicationsAntihypertensive therapyCohort studyHypertension developmentBP dropHospitalized patientsPulmonary diseaseTreatment guidelinesBP treatmentWorse outcomesTreatment decisionsCardiac arrythmiasPatientsPotassium levelsHigh potassium levelsLogistic regressionDemographic characteristics
2011
Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study
Hu M, Gucalp R, Insogna K, Glezerman I, Leboulleux S, Misiorowski W, Yu B, Ying W, Yeh H. Denosumab for Treatment of Hypercalcemia of Malignancy in Patients with Solid Tumors or Hematological Malignancies Refractory to IV Bisphosphonates: A Single-Arm Multicenter Study. Blood 2011, 118: 2483. DOI: 10.1182/blood.v118.21.2483.2483.Peer-Reviewed Original ResearchHypercalcemia of malignancyDose of denosumabTreatment of hypercalcemiaAdverse eventsBP treatmentInterim analysisDay 10RANK ligandComplete responseAdvanced cancerCSC levelsBone resorptionHematological malignanciesTreatment of HCMSolid tumorsSingle-arm multicenter studyAmgen Inc.Denosumab-treated patientsDoses of denosumabStudy day 10Serious adverse eventsSerum calcium levelsSingle-arm studyStudy days 1Population of patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply